Updates are available Correction dated 2023-05-08

Article History

Received: 18 December 2022

Accepted: 27 March 2023

First Online: 11 April 2023

Change Date: 8 May 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00262-023-03457-9

Declarations

:

: M.S. receives industry research support from Amgen, BMS/Celgene, Gilead, Janssen, Miltenyi Biotec, Morphosys, Novartis, Roche, Seattle Genetics and Takeda. She serves as a consultant/advisor to AvenCell, CDR-Life, Ichnos Sciences, Incyte Biosciences, Janssen, Miltenyi Biotec, Molecular Partners, Novartis, Pfizer and Takeda and serves on the speakers' bureau at Amgen, AstraZeneca, BMS/Celgene, Gilead, GSK, Janssen, Novartis, Pfizer, Roche and Takeda. V.L.B. has received research funding from Miltenyi Biotec, Novartis, and Pfizer, and has served as a consultant/advisor to Novartis, Amgen, and Gilead. He serves on the speakers’ bureau at Novartis and Pfizer. R.K. is employed at Amgen Research Munich, Germany. S.M.L. (now employed at iOmx Therapeutics AG) received research funding from Roche. S.T. has served as a consultant/advisor to Amgen, BMS, GSK, Janssen, Pfizer, Sanofi, and Takeda. S.K. has received honoraria from TCR2, Inc., Novartis, BMS and GSK. S.K. is inventor of several patents in the field of immunooncology. S.K. received license fees from TCR2, Inc., and Carina Biotech. S.K. received research support from TCR2, Inc., Tabby Therapeutics, Plectonic GmBH and Arcus Bioscience for work unrelated to the paper. A.M., B.B. (now employed at Adivo GmbH), L.R., G.H., F.M., T.S., N.P., K.S., and J.R.J. declare no relevant conflicts of interest.

: PB samples from HDs and samples of PB and BM from AML patients were collected with written consent in accordance with the Declaration of Helsinki and with approval from the Institutional Review Board of LMU Munich.

: Not applicable.